Amends the Federal Food, Drug, and Cosmetic Act to allow the holder of an approved new drug application to distribute in any manner to a…
Official title: To amend the Federal Food, Drug, and Cosmetic Act to revise the requirements of that Act relating to the dissemination of scientific information on drugs.
This bill died when its Congress ended.
Bills don't carry over between Congresses. Without re-introduction in a new session, it cannot advance.
Amends the Federal Food, Drug, and Cosmetic Act to allow the holder of an approved new drug application to distribute in any manner to a health professional (including insurers) a reprint of an article in an independent peer-reviewed medical textbook, journal, or medical compendium if the reprint is accompanied by a copy of the package insert and a statement that the reprint has not been approved by the Food and Drug Administration. Declares that the reprints shall not be regulated as advertising or labeling. Prohibits the Secretary of Health and Human Services from preventing advertising or labeling regarding an approved indication for a new drug, and for any pharmacoeconomic information relating to a drug, unless the Secretary determines in writing that the advertising or labeling is likely to cause unsafe or ineffective misuse.
Filed in the House
This house bill has been filed and is working its way through Congress. It will need to pass both the House and the Senate, then be signed by the President to become law.
Who introduced this
Ask AI About This Bill
Get plain-language answers with direct quotes from the bill text.
Your Representatives
Enter your address to see how your representatives voted on this bill.
Your address is only used to find your district and is never saved. See how it works
Votes
Public Opinion
No votes yet — be the first to weigh in.
to cast your vote
Your voice matters — let representatives know where you stand.
Comments
No comments yet. to be the first to weigh in.